Related Experiment Videos
CD22-directed monoclonal antibody therapy for lymphoma
Abby B Siegel1, David M Goldenberg, Alessandra Cesano
1Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York, NY, USA.
Seminars in Oncology
|August 27, 2003
Summary
Epratuzumab, an anti-CD22 antibody, shows promise for treating B-cell non-Hodgkin
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- CD20-targeted immunotherapy has significantly advanced B-cell non-Hodgkin's lymphoma (NHL) treatment.
- Antibody therapies offer a good safety profile and complement cytotoxic treatments.
- CD22 is a B-cell specific antigen expressed in NHL, crucial for B-cell biology.
Purpose of the Study:
- To evaluate the antilymphoma effects and safety of epratuzumab, a humanized anti-CD22 monoclonal antibody.
- To explore the potential of targeting CD22 in NHL treatment.
Main Methods:
- Preclinical studies.
- Early clinical trials of epratuzumab.
- Evaluation of both unlabeled and radiolabeled forms of the antibody.
Main Results:
- Epratuzumab demonstrated antilymphoma effects in preclinical and early clinical studies.
- The antibody exhibited a favorable safety profile.
- Both unlabeled and radiolabeled forms showed efficacy.
Conclusions:
- Epratuzumab targeting CD22 presents a potential therapeutic option for B-cell NHL.
- Further studies are needed to define its role as a single agent or in combination therapy.